$PAX

Patria (PAX) Q2 2026 Earnings Call Transcript

Patria (PAX) reported Q2 2026 fundraising of $2.3B, bringing YTD to $4.5B toward a $7B annual target. Fee-earning AUM rose to $48.9B. Fee-related earnings were $57.1M and FRE per share was $0.32. Full-year 2026 FRE guidance is $225M to $245M, with 2027 target $260M to $290M. The company also completed a $350M bond offering and declared a $0.1625 dividend.

Original reporting
Published Aug 8, 2026, 4:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 4:55 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Patria (PAX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PAXNeutralMed
01

Why it matters

The key tradable items are the explicit 2026 FRE guidance range, the updated expectation for FRE margin below target, and the 2027 FRE target, all framed around acquisition integration pace and fundraising momentum.

02

Market read

Traders can reprice near-term earnings expectations using the updated 2026 FRE margin outlook and guidance, while monitoring whether fundraising strength offsets integration-driven cost pressure.

03

What to watch

Underperforming buyout funds were marked down, and the call attributes margin pressure to acquisition timing, so investors may focus on whether integration costs normalize faster than expected.

Relevance 8/10Novelty 7/10Timing: pre-market today, after-hours earnings call transcript

Background

Patria reported Q2 2026 fundraising and fee metrics and discussed integration of recent acquisitions, including WP Global Partners and Solis, on its earnings call.

Company-level read

Ticker impact

$PAXNeutralMedium confidence
Context

Patria guided full-year 2026 FRE to $225M-$245M and said FRE margin will fall modestly below its 58%-60% target due to faster acquisition integration.

Expected impact

Likely choppy reaction, with upside support from fundraising momentum and downside risk from the margin reset.

Evidence & confidence

The call provides explicit 2026 FRE guidance and a margin outlook change, which are direct earnings drivers, while other positives (fee-earning AUM, distributable EPS, capital formation) may temper the impact.

Market effects

Signals continued demand for private markets solutions (credit and multiasset mandates) but highlights integration-driven margin volatility for alternative asset managers.

Mentions improving North America fundraising and macro headwinds in Brazil affecting underperforming buyout funds.

South America political shift commentary (Chile, Colombia) suggests improving risk appetite for regional private markets fundraising.

Counterpoint

The margin miss may be temporary, since the company also raised visibility via pending fee-earning AUM and expects higher 2027 FRE targets.

Key entities

  • Patria

    Alternative asset manager reporting Q2 2026 results, fundraising, and issuing full-year FRE guidance and 2027 targets.

  • Alexandre Saigh

    CEO who discussed margin outlook, marked-down underperforming buyout funds, and future M&A selectivity.

  • Raphael Denadai

    CFO who commented on FRE margin expectations for full-year 2026.

Related articles

$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

$FTSMed

Fortis (FTS) Q2 2026 Earnings Call Transcript

Fortis (FTS) reported Q2 2026 net earnings of C$396 million, up C$26 million year over year, and EPS of C$0.78. Capital expenditures were C$2.7 billion through June, with a C$5.6 billion 2026 plan. Management reiterated 4% to 6% dividend growth through 2030 and cited Tilbury LNG Phase 1B approval and a 9.75% ROE request in an Arizona rate case.

$ANMed

AutoNation (AN) Q2 2026 Earnings Call Transcript

AutoNation (AN) reported Q2 2026 adjusted diluted EPS of $5.56, up 2% year over year, with total revenue of $6.93 billion, essentially flat. After-sales gross profit was a record $607 million, and Customer Financial Services profitability rose to $2,800 per vehicle. ANF net income increased to $11 million and the portfolio grew to $2.67 billion. The company repurchased $457 million of shares and acquired four stores.

$DOCMed

Healthpeak Properties Q2 Earnings Call Highlights

Healthpeak Properties (NYSE:DOC) highlighted Q2 results and updates on capital recycling and leasing. It recapitalized a Brookfield outpatient portfolio, retaining 51% interest and raising $1B cash, and noted a 5.9% trailing cash cap rate. Lab occupancy rose to 78.5%. Net debt/adj. EBITDA was 4.7x with $4.1B liquidity; it repaid $900M debt and repurchased $100M shares.

$MTDHighAI 9/10

Mettler-Toledo (MTD) Q2 2026 Earnings Call Transcript

Mettler-Toledo (MTD) reported Q2 2026 net sales of $1.027B, up 4% reported (6% local currency). Adjusted EPS was $11.46, up 14%. Adjusted operating margin was 29.3%. The company raised full-year 2026 guidance to 4% to 5% local currency revenue growth and adjusted EPS of $47.15 to $47.50, and plans $875M share repurchases.